Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT03585660 Recruiting - Prostate Cancer Clinical Trials

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

Start date: June 19, 2018
Phase: N/A
Study type: Interventional

The purpose of the proposed research is to test and validate an artificial intelligence-based Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).

NCT ID: NCT03585114 Not yet recruiting - Clinical trials for Metastatic Prostate Cancer

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Start date: August 2018
Phase: Phase 2
Study type: Interventional

Primary Objective: - To determine whether changes in uptake of [18F]DCFPyL PET/CT scans at baseline and after 6 weeks of treatment for metastatic castrate resistant prostate cancer, correlates with radiographic progression free survival (rPFS) as defined by Prostate Cancer Working Group 3 (PCWG3) criteria. Secondary Objectives: - To determine whether changes in uptake of [18F]DCFPyL PET/CT scans correlate with overall survival (OS) - To determine whether baseline SUVmax correlate with rPFS - To compare number of lesions detected with standard imaging at baseline and at the time of progression

NCT ID: NCT03582774 Not yet recruiting - Clinical trials for Recurrent Prostate Carcinoma

Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]

Start date: July 30, 2018
Phase: Phase 3
Study type: Interventional

For men with a recurrence following radical prostatectomy, salvage external beam radiation therapy (SRT) can provide long-term disease control if the recurrence is encompassed within the treatment field and a sufficient radiation dose can be delivered to eradicate the residual/recurrent cancer. SRT offers long-term biochemical control in about 60% of patients. Target volume delineations for prostate cancer SRT after radical prostatectomy are usually drawn in the absence of visibly recurrent disease.

NCT ID: NCT03582475 Not yet recruiting - Clinical trials for Urothelial Carcinoma

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Start date: July 27, 2018
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes or that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as etoposide, docetaxel, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with platinum-based chemotherapy may work better in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate.

NCT ID: NCT03581500 Not yet recruiting - Clinical trials for Prostate Adenocarcinoma

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Participants With Prostate Cancer

Start date: November 7, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well hyperpolarized carbon C 13 pyruvate magnetic resonance spectroscopic imaging works in predicting treatment response in participants with prostate cancer. Hyperpolarized carbon C 13 pyruvate magnetic resonance spectroscopic imaging may help to accurately predict how prostate cancer patients will respond to standard therapy (abiraterone and apalutamide).

NCT ID: NCT03580499 Not yet recruiting - Hot Flashes Clinical Trials

Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy

Start date: December 2018
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well vitamin B6 works in reducing hot flashes in participants with prostate cancer undergoing antiandrogen therapy. A nutritional supplement such as vitamin B6 may help improve hot flashes caused by antiandrogen therapy in participants with prostate cancer.

NCT ID: NCT03580239 Not yet recruiting - Prostate Cancer Clinical Trials

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

Investigators seek a new therapeutic strategy for castrated resistant prostate cancer(CRPC) patients with PI3K-AKT-mTOR signaling pathway deficiency by next generation sequencing(NGS).

NCT ID: NCT03579680 Not yet recruiting - Cancer of Prostate Clinical Trials

De-implementation of Low Value Castration for Men With Prostate Cancer

DeADT
Start date: July 2018
Phase:
Study type: Observational

Make this about Aim 1 Use "the study" and not "we" language No promotional language/no amount of compensation/spell out acryonym first time This study will use a theory-based, mixed methods approach to identify, tailor and pilot two different de-implementation strategies that vary widely in delivery, impact, and expected results for reducing low value androgen deprivation therapy (ADT) use in preparation for a randomized comparative effectiveness trial.

NCT ID: NCT03579654 Not yet recruiting - Prostate Cancer Clinical Trials

Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

Start date: August 15, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with low-risk localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years following administration of Proscavax or active surveillance, the effect of the vaccine on prostate-specific antigen (PSA) doubling time and the assessment of adverse events in these patients. Eligible patients in this study will include men who are 18 years and older and who have a previously untreated early stage prostate cancer regardless of the date of diagnosis.

NCT ID: NCT03577028 Not yet recruiting - Clinical trials for Advanced Prostate Cancer

Study of HPN424 in Patients With Advanced Prostate Cancer

Start date: July 2018
Phase: Phase 1
Study type: Interventional

An open-label, Phase 1, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy